Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
IPO Year: 2020
Exchange: NASDAQ
Website: fusionpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/27/2023 | $12.00 → $15.00 | Outperform → Strong Buy | Raymond James |
| 9/29/2023 | $13.00 | Outperform | Oppenheimer |
| 6/23/2023 | $13.00 | Outperform | Raymond James |
| 12/1/2022 | $10.00 | Buy | B. Riley Securities |
| 11/30/2022 | $6.00 | Outperform | SVB Leerink |
| 9/16/2022 | $10.00 | Buy | Truist |
| 7/6/2022 | Outperform | William Blair | |
| 10/19/2021 | $19.00 | Overweight | Morgan Stanley |
| 8/26/2021 | $17.00 | Buy | B. Riley Securities |
| 8/18/2021 | $20.00 → $19.00 | Overweight | Morgan Stanley |
Preliminary Clinical Data with Cold/Hot Dosing Regimen Demonstrate Potential to Improve Therapeutic Index and Safety Profile Company Prioritizing Cold/Hot Dosing Regimen in Phase 1 Trial; Cohort 2 in this Arm is Currently Enrolling Data to be Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting Fusion to Host Conference Call Tomorrow, Tuesday, June 27th at 4:00 p.m. ET/3:00 p.m. CT HAMILTON, ON and BOSTON, June 26, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of interim data from the do
Company recently acquired IND for ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T, a small molecule radiopharmaceutical targeting PSMA positive mCRPC FPI-1434 preliminary Phase 1 data expected in Q2 2023 FPI-1966 and FPI-2059 Phase 1 trials open and recruiting patients Strong balance sheet with runway into Q1 2025 supports ongoing execution of multiple clinical programs HAMILTON, ON and BOSTON, March 16, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the fourth quarter ended December 31, 2022 and provided an updat
Phase 1 study of FPI-1434 Phase 1 enrollment continues on track for data in 1H2022 Continuing expansion of pipeline of targeted alpha therapies through recently completed transactions HAMILTON, ON and BOSTON, May 11, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the first quarter ended March 31, 2021 and provided an update on clinical and corporate developments. "We continue to advance our Phase 1 study
4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)
4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)
4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)
4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)
4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)
4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)
4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)
4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)
4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)
4 - Fusion Pharmaceuticals Inc. (0001805890) (Issuer)
SC 13G/A - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
SC 13D - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
SC 13D/A - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
SC 13D/A - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
SC 13G/A - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
SC 13G/A - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
SC 13G/A - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
SC 13G - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
SC 13G/A - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
SC 13G - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced that at a special meeting of its shareholders (the "Shareholders"), held virtually earlier today, the Shareholders voted in favour of the resolution to approve the previously announced plan of arrangement with a wholly-owned subsidiary of AstraZeneca under the Canada Business Corporations Act pursuant to which AstraZeneca will acquire all of the issued and outstanding shares of Fusion (the "Arrangement").
AlphaBreak is a Phase 2/3 registrational program for FPI-2265 in patients with metastatic castration-resistant prostate cancerHAMILTON, ON and BOSTON, May 9, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced that the first patient has been dosed in the Phase 2 portion of the AlphaBreak trial evaluating FPI-2265 (225Ac-PSMA I&T) in patients with metastatic castration-resistant prostate cancer (mCRPC)."Actinium-based PSMA targeting RCs have demonstrated compelling safety and clinical activity, which is supported by Fusion's encouraging data from the Phase
Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.37) by 8.11 percent. This is a 11.11 percent increase over losses of $(0.45) per share from the same period last year.
As of April 26, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here's the latest list of major overbought players in this sector. Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) AstraZeneca, through a subsidiary, will acquire
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision medicines, today announced that it has filed and is in the process of mailing the management information circular and proxy statement (the "Circular") and related materials for the special meeting (the "Meeting") of Fusion's shareholders (the "Shareholders") to approve the previously announced arrangement with AstraZeneca plc ("AstraZeneca") under the Canada Business Corporations Act (the "Arrangement").Under the terms of the Arrangement, AstraZeneca, through a subsidiary, will acquire all of Fusion's outstanding shares for a price of US$21.00
TD Cowen analyst Tara Bancroft downgrades Fusion Pharmaceuticals (NASDAQ:FUSN) from Buy to Hold.
Thursday, AstraZeneca Plc (NASDAQ:AZN) raised its annualized dividend for 2024 by $0.20 to $3.10 per share, underlining the company’s confidence in its performance and cash generation. The company said the 7% increase takes into account other capital allocation priorities and previously announced acquisitions and business development. Michel Demaré, Chair, AstraZeneca, said: “This uplift is in line with our progressive dividend policy, which remains unchanged, and reflects the continuing strength of AstraZeneca’s investment proposition for shareholders.” Also Read: AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race.
AstraZeneca Plc’s (NASDAQ:AZN) Chief Executive Pascal Soriot says the company achieved a significant milestone by reaching a sales target of $45 billion by 2023, a goal set a decade ago amid pressure from U.S. rival Pfizer Inc (NYSE:PFE). In November 2013, AstraZeneca received an initial contact on Pfizer’s behalf, proposing that the two companies discuss a combination. AstraZeneca said it was not appropriate to engage in discussions with Pfizer. Initially facing challenges with revenues at $26 billion and patent expiries, Soriot celebrated the achievement amidst skepticism. However, despite hitting this milestone, Soriot faces the challenge of convincing investors that AstraZeneca
15-12G - Fusion Pharmaceuticals Inc. (0001805890) (Filer)
EFFECT - Fusion Pharmaceuticals Inc. (0001805890) (Filer)
EFFECT - Fusion Pharmaceuticals Inc. (0001805890) (Filer)
EFFECT - Fusion Pharmaceuticals Inc. (0001805890) (Filer)
25-NSE - Fusion Pharmaceuticals Inc. (0001805890) (Subject)
POS AM - Fusion Pharmaceuticals Inc. (0001805890) (Filer)
POS AM - Fusion Pharmaceuticals Inc. (0001805890) (Filer)
POS AM - Fusion Pharmaceuticals Inc. (0001805890) (Filer)
S-8 POS - Fusion Pharmaceuticals Inc. (0001805890) (Filer)
S-8 POS - Fusion Pharmaceuticals Inc. (0001805890) (Filer)
HAMILTON, ON and BOSTON, June 4, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), announced the successful completion of the acquisition of all of the issued and outstanding shares of Fusion by a wholly-owned subsidiary of AstraZeneca AB by way of a statutory plan of arrangement under section 192 of the Canada Business Corporations Act, referred to as the Arrangement. The Arrangement marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more
HAMILTON, ON and BOSTON, May 31, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced it has obtained a final order from the Ontario Superior Court of Justice (Commercial List) approving the previously announced statutory plan of arrangement under Section 192 of the Canada Business Corporations Act, pursuant to which a wholly-owned subsidiary of AstraZeneca will acquire all issued and outstanding shares of Fusion (the "Arrangement"). Fusion shareholders will receive US$21.00 per share in cash upfront on completion of the Arrangement plus a deferred
HAMILTON, ON and BOSTON, May 29, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced that at a special meeting of its shareholders (the "Shareholders"), held virtually earlier today, the Shareholders voted in favour of the resolution to approve the previously announced plan of arrangement with a wholly-owned subsidiary of AstraZeneca under the Canada Business Corporations Act pursuant to which AstraZeneca will acquire all of the issued and outstanding shares of Fusion (the "Arrangement").
AlphaBreak is a Phase 2/3 registrational program for FPI-2265 in patients with metastatic castration-resistant prostate cancer HAMILTON, ON and BOSTON, May 9, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced that the first patient has been dosed in the Phase 2 portion of the AlphaBreak trial evaluating FPI-2265 (225Ac-PSMA I&T) in patients with metastatic castration-resistant prostate cancer (mCRPC). "Actinium-based PSMA targeting
Presented interim data from TATCIST trial of FPI-2265 in mCRPC at the 2024 American Association for Cancer Research (AACR) Annual Meeting Signed definitive agreement to be acquired by AstraZeneca for total transaction value of up to $2.4 billion; transaction expected to close in the second quarter of 2024 HAMILTON, ON and BOSTON, May 7, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today reported financial results for the first quarter ended March 31, 2024, and provided an update on clinical and corporate developments.
HAMILTON, ON and BOSTON, April 25, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision medicines, today announced that it has filed and is in the process of mailing the management information circular and proxy statement (the "Circular") and related materials for the special meeting (the "Meeting") of Fusion's shareholders (the "Shareholders") to approve the previously announced arrangement with AstraZeneca plc ("AstraZeneca") under the Canada Business Corporations Act (the "Arrangement").
Preliminary data demonstrate FPI-2265 is active in heavily pretreated patients with progressive metastatic castration-resistant prostate cancer (mCRPC), including those who received prior lutetium-based radioconjugates HAMILTON, ON and BOSTON, April 9, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced the presentation of interim efficacy and safety data from the Phase 2 TATCIST open-label clinical trial evaluating FPI-2265, at the American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10 in San Diego, California.
Company recently announced definitive agreement to be acquired by AstraZeneca FPI-2265 Phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mCRPC) expected to begin in Q2 2024 Interim data from TATCIST study of FPI-2265 to be presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting in April Fusion is now producing and shipping clinical doses of FPI-2265 from its state-of-the-art GMP manufacturing facility HAMILTON, ON and BOSTON, March 20, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines,
Transaction includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate cancer, pipeline of radioconjugates and state-of-the-art R&D and manufacturing facilities Fusion shareholders to receive $21.00 per share in cash at closing plus a non-transferrable contingent value right (CVR) of $3.00 per share, representing a total transaction value of approximately $2.4 billion including the CVR HAMILTON, ON and BOSTON, March 19, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced the Company has entered into a definitive agreement to
HAMILTON, ON and BOSTON, March 6, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the compensation committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 245,300 shares of its common stock to four employees outside Fusion's 2020 Stock Option and Incentive Plan. The stock options were granted as an inducement material to the individual becoming an employee of Fusion in accordance with Nasdaq Listing Rule 5635(c)(4).
Raymond James upgraded Fusion Pharmaceuticals from Outperform to Strong Buy and set a new price target of $15.00 from $12.00 previously
Oppenheimer initiated coverage of Fusion Pharmaceuticals with a rating of Outperform and set a new price target of $13.00
Raymond James initiated coverage of Fusion Pharmaceuticals with a rating of Outperform and set a new price target of $13.00
B. Riley Securities resumed coverage of Fusion Pharmaceuticals with a rating of Buy and set a new price target of $10.00
SVB Leerink initiated coverage of Fusion Pharmaceuticals with a rating of Outperform and set a new price target of $6.00
Truist initiated coverage of Fusion Pharmaceuticals with a rating of Buy and set a new price target of $10.00
William Blair initiated coverage of Fusion Pharmaceuticals with a rating of Outperform
Morgan Stanley resumed coverage of Fusion Pharmaceuticals with a rating of Overweight and set a new price target of $19.00
B. Riley Securities initiated coverage of Fusion Pharmaceuticals with a rating of Buy and set a new price target of $17.00
Morgan Stanley reiterated coverage of Fusion Pharmaceuticals with a rating of Overweight and set a new price target of $19.00 from $20.00 previously
FPI-1434 Phase 1 data on track to be reported in first half of 2023 Phase 1/2 Study of FPI-1966 open and enrolling patients with solid tumors expressing FGFR3 Strong balance sheet with $205.5 million in cash, cash equivalents and investments with runway into Q3 2024 HAMILTON, ON and BOSTON, Nov. 8, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the third quarter ended September 30, 2022 and provided an update on clinical and corporate developments.
HAMILTON, ON and BOSTON, Nov. 7, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Dmitri Bobilev, M.D., as chief medical officer. "We are pleased to welcome Dmitri to Fusion's leadership team at a time when Fusion has three Phase 1 novel targeted alpha therapy (TAT) programs and a multi-product development collaboration with AstraZeneca," said Fusion Chief Executive Officer John Valliant, Ph.D. "Dmitri brings to
- Eric Burak, Ph.D. Appointed as Chief Technology Officer HAMILTON, Ontario and BOSTON, Nov. 2, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Christopher Leamon, Ph.D., as chief scientific officer. Dr. Leamon brings to Fusion more than 25 years of experience developing precision medicines and radiopharmaceuticals. "Chris' expertise and success in radiopharmaceutical research and development is scarce in our
HAMILTON, ON and BOSTON, Sept. 28, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Mohit Rawat as President and Chief Business Officer. Mr. Rawat brings to Fusion more than 15 years of experience in the biopharmaceutical industry, with expertise in corporate strategy, business development and commercial execution, including product development, launch planning and commercialization. "We are delighted to welcome
HAMILTON, ON and BOSTON, Sept. 21, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Eric S. Hoffman, Ph.D. as senior vice president, business development. "The field of radiopharmaceuticals is experiencing a resurgence of interest and excitement, and Fusion is well-positioned with a platform to create differentiated targeted alpha therapies (TATs) from a wide range of targeting molecules, including antibodies and
HAMILTON, ON and BOSTON, June 7, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Isabelle Dussault, Ph.D. as senior vice president, research. "Isabelle brings deep oncology research experience, including antibody-drug conjugate, biomarker and immuno-oncology expertise, to our team and we are pleased to welcome her," said Chief Executive Officer John Valliant, Ph.D. "Fusion's research capabilities are a core pillar of our platform. We look forward to Isabelle's contributions to expanding our pipeline of radiopharmaceuticals in
HAMILTON, ON and BOSTON, April 1, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines today announced the appointment of Donald A. Bergstrom, M.D., Ph.D., as a member of the Company's Board of Directors. Dr. Bergstrom, who currently serves as executive vice president, head of research and development at Relay Therapeutics, Inc., a clinical stage precision medicines company, brings to the board more than 15 years of experience in the biopharmaceutical industry. "Don's depth of precision oncology and industry experience will be invaluable to us as we continue to pro
HAMILTON, Ontario and BOSTON, Feb. 11, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Philina Lee, Ph.D., as a member of the Company's Board of Directors. Dr. Lee, who currently serves as senior vice president, head of portfolio strategy at Blueprint Medicines Corporation, brings to the board 15 years of experience in the biopharmaceutical industry. She previously was head of U.S. marketing for Algeta, developer of the first marketed alpha-emitting radiopharmaceutical. "Philina's depth of both precision oncology and radi